The NIH and other agencies are funding high-throughput genomics (?omics) experiments that deposit digital samples of data into the public domain at breakneck speeds. This high-quality data measures the ?omics of diseases, drugs, cell lines, model organisms, etc. across the complete gamut of experimental factors and conditions. The importance of these digital samples of data is further illustrated in linked peer-reviewed publications that demonstrate its scientific value. However, meta-data for digital samples is recorded as free text without biocuration necessary for in-depth downstream scientific inquiry. Deep learning is revolutionary machine intelligence paradigm that allows for an algorithm to program itself thereby removing the need to explicitly specify rules or logic. Whereas physicians / scientists once needed to first understand a problem to program computers to solve it, deep learning algorithms optimally tune themselves to solve problems. Given enough example data to train on, deep learning machine intelligence outperform humans on a variety of tasks. Today, deep learning is state-of-the-art performance for image classification, and, most importantly for this proposal, for natural language processing. This proposal is about engineering Crowd Assisted Deep Learning (CrADLe) machine intelligence to rapidly scale the digital curation of public digital samples. We will first use our NIH BD2K-funded Search Tag Analyze Resource for Gene Expression Omnibus (STARGEO.org) to crowd-source human annotation of open digital samples. We will then develop and train deep learning algorithms for STARGEO digital curation based on learning the associated free text meta-data each digital sample. Given the ongoing deluge of biomedical data in the public domain, CrADLe may perhaps be the only way to scale the digital curation towards a precision medicine ideal. Finally, we will demonstrate the biological utility to leverage CrADLe for digital curation with two large- scale and independent molecular datasets in: 1) The Cancer Genome Atlas (TCGA), and 2) The Accelerating Medicines Partnership-Alzheimer?s Disease (AMP-AD). We posit that CrADLe digital curation of open samples will augment these two distinct disease projects with a host big data to fuel the discovery of potential biomarker and gene targets. Therefore, successful funding and completion of this work may greatly reduce the burden of disease on patients by enhancing the efficiency and effectiveness of digital curation for biomedical big data.

Public Health Relevance

This proposal is about engineering Crowd Assisted Deep Learning (CrADLe) machine intelligence to rapidly scale the digital curation of public digital samples and directly translating this ?omics data into useful biological inference. We will first use our NIH BD2K-funded Search Tag Analyze Resource for Gene Expression Omnibus (STARGEO.org) to crowd-source human annotation of open digital samples on which we will develop and train deep learning algorithms for STARGEO digital curation of free-text sample-level metadata. Given the ongoing deluge of biomedical data in the public domain, CrADLe may perhaps be the only way to scale the digital curation towards a precision medicine ideal.

Agency
National Institute of Health (NIH)
Institute
National Library of Medicine (NLM)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01LM012675-02
Application #
9527181
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Florance, Valerie
Project Start
2017-08-01
Project End
2021-07-31
Budget Start
2018-08-01
Budget End
2019-07-31
Support Year
2
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94118
Hadley, Dexter; Pan, James; El-Sayed, Osama et al. (2017) Precision annotation of digital samples in NCBI's gene expression omnibus. Sci Data 4:170125
Himmelstein, Daniel Scott; Lizee, Antoine; Hessler, Christine et al. (2017) Systematic integration of biomedical knowledge prioritizes drugs for repurposing. Elife 6: